Sofosbuvir Off-label Treatment of Yellow Fever Patients During an Outbreak in Brazil, 2018: A Cohort Study.
Izabela Maurício de RezendeDiogo Correa MendonçaThais Alkifeles CostaGabriela Fernanda Garcia de OliveriaMatheus Soares ArrudaAndreza Parreiras GonçalvesPedro Augusto AlvesCarlos Eduardo Calzavara-SilvaOlindo A Martins-FilhoAndréa Teixeira-CarvalhoClaudio Antonio BonjardimThomas P MonathA Desiree LaBeaudBetânia P DrumondMarcelo Antônio Pascoal-XavierLeonardo S PereiraDario Brock RamalhoPublished in: Open forum infectious diseases (2024)
We enrolled 21 patients with laboratory-confirmed yellow fever (YF), hospitalized at Eduardo de Menezes Hospital, Brazil, to be treated with sofosbuvir, a drug approved for hepatitis C. Given the absence of specific YF antiviral treatments, the off-label nonrandomized sofosbuvir treatment aimed to address high disease severity and the risk of fatal outcomes. Patients received a daily dose of 400 mg sofosbuvir from 4 to 10 days post-symptom onset. YF viral load (VL) comparisons were made between treated and nontreated patients who either survived or died. The genomic VL for the treated group steadily decreased after day 7 post-symptom onset, suggesting that sofosbuvir might reduce YF VL. This study underscores the urgent need for YF antiviral therapies, advocating for randomized clinical trials to further explore sofosbuvir's role in YF treatment.